Search

Your search keyword '"Llorca, F."' showing total 10 results
Start Over Author "Llorca, F." Journal esmo open
10 results on '"Llorca, F."'

1. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

Author

Penault-Llorca, F., Dalenc, F., Chabaud, S., Cottu, P., Allouache, D., Cameron, D., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Barthelemy, P., Kaluzinski, L., Mailliez, A., Mouret-Reynier, M.-A., Legouffe, E., Cayre, A., Martinez, M., Delbaldo, C., Mollon-Grange, D., Macaskill, E.J., Sephton, M., Stefani, L., Belgadi, B., Winter, M., Orfeuvre, H., Lacroix-Triki, M., Bonnefoi, H., Bliss, J., Canon, J.-L., Lemonnier, J., Andre, F., and Bachelot, T.

Published
2024
Full Text
View/download PDF

2. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

Author

Hofman, P., Calabrese, F., Kern, I., Adam, J., Alarcão, A., Alborelli, I., Anton, N.T., Arndt, A., Avdalyan, A., Barberis, M., Bégueret, H., Bisig, B., Blons, H., Boström, P., Brcic, L., Bubanovic, G., Buisson, A., Caliò, A., Cannone, M., Carvalho, L., Caumont, C., Cayre, A., Chalabreysse, L., Chenard, M.P., Conde, E., Copin, M.C., Côté, J.F., D’Haene, N., Dai, H.Y., de Leval, L., Delongova, P., Denčić-Fekete, M., Fabre, A., Ferenc, F., Forest, F., de Fraipont, F., Garcia-Martos, M., Gauchotte, G., Geraghty, R., Guerin, E., Guerrero, D., Hernandez, S., Hurník, P., Jean-Jacques, B., Kashofer, K., Kazdal, D., Lantuejoul, S., Leonce, C., Lupo, A., Malapelle, U., Matej, R., Merlin, J.L., Mertz, K.D., Morel, A., Mutka, A., Normanno, N., Ovidiu, P., Panizo, A., Papotti, M.G., Parobkova, E., Pasello, G., Pauwels, P., Pelosi, G., Penault-Llorca, F., Picot, T., Piton, N., Pittaro, A., Planchard, G., Poté, N., Radonic, T., Rapa, I., Rappa, A., Roma, C., Rot, M., Sabourin, J.C., Salmon, I., Prince, S. Savic, Scarpa, A., Schuuring, E., Serre, I., Siozopoulou, V., Sizaret, D., Smojver-Ježek, S., Solassol, J., Steinestel, K., Stojšić, J., Syrykh, C., Timofeev, S., Troncone, G., Uguen, A., Valmary-Degano, S., Vigier, A., Volante, M., Wahl, S.G.F., Stenzinger, A., and Ilié, M.

Published
2023
Full Text
View/download PDF

5. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Author

Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., and Beaupere, S.

Published
2021
Full Text
View/download PDF

6. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Author

Hofman, P., Ilié, M., Chamorey, E., Brest, P., Schiappa, R., Nakache, V., Antoine, M., Barberis, M., Begueret, H., Bibeau, F., Bonnetaud, C., Boström, P., Brousset, P., Bubendorf, L., Carvalho, L., Cathomas, G., Cazes, A., Chalabreysse, L., Chenard, M.-P., Copin, M.-C., Côté, J.-F., Damotte, D., de Leval, L., Delongova, P., Thomas de Montpreville, V., de Muret, A., Dema, A., Dietmaier, W., Evert, M., Fabre, A., Forest, F., Foulet, A., Garcia, S., Garcia-Martos, M., Gibault, L., Gorkiewicz, G., Jonigk, D., Gosney, J., Hofman, A., Kern, I., Kerr, K., Kossai, M., Kriegsmann, M., Lassalle, S., Long-Mira, E., Lupo, A., Mamilos, A., Matěj, R., Meilleroux, J., Ortiz-Villalón, C., Panico, L., Panizo, A., Papotti, M., Pauwels, P., Pelosi, G., Penault-Llorca, F., Pop, O., Poté, N., Cajal, S.R.Y., Sabourin, J.-C., Salmon, I., Sajin, M., Savic-Prince, S., Schildhaus, H.-U., Schirmacher, P., Serre, I., Shaw, E., Sizaret, D., Stenzinger, A., Stojsic, J., Thunnissen, E., Timens, W., Troncone, G., Werlein, C., Wolff, H., Berthet, J.-P., Benzaquen, J., Marquette, C.-H., Hofman, V., and Calabrese, F.

Published
2021
Full Text
View/download PDF

9. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Author

John R. Gosney, G. Troncone, W. Dietmaier, A. De Muret, P. Brest, S.R.Y. Cajal, E. Long-Mira, G. Gorkiewicz, H. Wolff, Lina Carvalho, J. Stojsic, A. Hofman, Izidor Kern, L. Chalabreysse, A. Dema, Cristian Ortiz-Villalón, R. Schiappa, Lukas Bubendorf, S. Garcia, L. Gibault, L. de Leval, M.-C. Copin, Aurélie Cazes, Hans-Ulrich Schildhaus, E. Shaw, M. Antoine, Véronique Hofman, A. Stenzinger, M. Garcia-Martos, M. Evert, V. Nakache, E. Chamorey, S. Savic-Prince, P. Boström, P. Brousset, M. Sajin, S. Lassalle, H. Begueret, Wim Timens, Mark Kriegsmann, Mauro Papotti, Peter Schirmacher, M.-P. Chenard, M. Barberis, V. Thomas de Montpreville, J. Meilleroux, P. Delongova, M. Ilié, C. Bonnetaud, C. Werlein, Keith M. Kerr, J.-F. Côté, A. Mamilos, A. Lupo, Patrick Pauwels, Frédérique Penault-Llorca, I. Serre, N. Poté, C.-H. Marquette, Paul Hofman, J.-C. Sabourin, J.-P. Berthet, Giuseppe Pelosi, A. Foulet, D. Damotte, D. Sizaret, Fabien Forest, Erik Thunnissen, A. Panizo, L. Panico, O. Pop, G. Cathomas, M. Kossai, I. Salmon, F. Calabrese, F. Bibeau, Aurelie Fabre, R. Matěj, J. Benzaquen, Danny Jonigk, Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Université Côte d'Azur (UCA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), European Institute of Oncology IRCCS [Milan, Italy] (EIO), CHU Bordeaux [Bordeaux], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Turku University Hospital (TYKS), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Basel [Basel], University of Coimbra [Portugal] (UC), Kantonsspital Baselland [Bruderholz] (KSBL), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Groupement Hospitalier Est [Bron], Hospices Civils de Lyon (HCL), CHU Strasbourg, CHU Lille, Université de Lille, Institut Mutualiste de Montsouris (IMM), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Lausanne (UNIL), University Hospital Ostrava, Centre chirurgical Marie Lannelongue, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Victor Babeş University of Medicine and Pharmacy (UMFT), University of Regensburg, University College Dublin [Dublin] (UCD), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Le Mans (CH Le Mans), Hôpital Nord AP‐MM Marseille, France (AP‐MM Marseille), Aix Marseille Université (AMU), Hospital General Universitario 'Gregorio Marañón' [Madrid], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Graz, Hannover Medical School [Hannover] (MHH), Royal Liverpool University Hospital, University of Liverpool-Royal Liverpool and Broadgreen University Hospital NHS Trust, University Clinic Golnik, Aberdeen Royal Infirmary, Aberdeen, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Heidelberg University Hospital [Heidelberg], Charles University [Prague] (CU), Karolinska University Hospital [Stockholm], Monaldi-Cotugno-CTO, Complejo Hospitalario de Navarra, Università degli studi di Torino (UNITO), University of Antwerp (UA), University of Milan, University of Oradea, Romania, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Vall d'Hebron University Hospital [Barcelona], Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Université libre de Bruxelles (ULB), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), University Hospital [Essen, Germany], Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University Hospital Southampton NHS Foundation Trust, University of Belgrade [Serbia], Institute of Zoology [Serbia], University of Amsterdam [Amsterdam] (UvA), University of Groningen [Groningen], Università degli studi di Napoli Federico II, Finnish Institute of Occupational Health of Helsinki, University of Padova Medical School, Université Nice Sophia Antipolis (1965 - 2019) (UNS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Université Côte d'Azur (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Université de Lausanne = University of Lausanne (UNIL), Centre Chirurgical Marie Lannelongue (CCML), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Karl-Franzens-Universität Graz, Università degli studi di Torino = University of Turin (UNITO), Università degli Studi di Milano = University of Milan (UNIMI), University of Oradea, Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University of Naples Federico II = Università degli studi di Napoli Federico II, Università degli Studi di Padova = University of Padua (Unipd), Institut Català de la Salut, [Hofman P, Ilié M, Nakache V] Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France. [Brest P] Team 4, IRCAN, INSERM, CNRS, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France. [Chamorey E, Schiappa R] Epidemiology and Biostatistics Unit, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France. [Cajal SRY] Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), COLO, Mouniati, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC), Karl-Franzens-Universität [Graz, Autriche], Hofman, P., Ilie, M., Chamorey, E., Brest, P., Schiappa, R., Nakache, V., Antoine, M., Barberis, M., Begueret, H., Bibeau, F., Bonnetaud, C., Bostrom, P., Brousset, P., Bubendorf, L., Carvalho, L., Cathomas, G., Cazes, A., Chalabreysse, L., Chenard, M. -P., Copin, M. -C., Cote, J. -F., Damotte, D., de Leval, L., Delongova, P., Thomas de Montpreville, V., de Muret, A., Dema, A., Dietmaier, W., Evert, M., Fabre, A., Forest, F., Foulet, A., Garcia, S., Garcia-Martos, M., Gibault, L., Gorkiewicz, G., Jonigk, D., Gosney, J., Hofman, A., Kern, I., Kerr, K., Kossai, M., Kriegsmann, M., Lassalle, S., Long-Mira, E., Lupo, A., Mamilos, A., Matej, R., Meilleroux, J., Ortiz-Villalon, C., Panico, L., Panizo, A., Papotti, M., Pauwels, P., Pelosi, G., Penault-Llorca, F., Pop, O., Pote, N., Cajal, S. R. Y., Sabourin, J. -C., Salmon, I., Sajin, M., Savic-Prince, S., Schildhaus, H. -U., Schirmacher, P., Serre, I., Shaw, E., Sizaret, D., Stenzinger, A., Stojsic, J., Thunnissen, E., Timens, W., Troncone, G., Werlein, C., Wolff, H., Berthet, J. -P., Benzaquen, J., Marquette, C. -H., Hofman, V., and Calabrese, F.

Subjects
Cancer Research, Pathology, [SDV]Life Sciences [q-bio], Medizin, Disease Outbreaks, varnost, Biosafety, 0302 clinical medicine, Surveys and Questionnaires, Pandemic, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine, Pathology, Molecular, COVID-19, activity, biosafety, lung cancer, pathology, biološka varnost, Health Occupations::Medicine::Pathology::Pathology, Clinical [DISCIPLINES AND OCCUPATIONS], Original Research, Biological Specimen Banks, 0303 health sciences, Pathology, Clinical, Molecular pathology, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Workload, Clinical Laboratory Services, Containment of Biohazards, Biobank, 3. Good health, [SDV] Life Sciences [q-bio], Europe, covid-19, Oncology, 030220 oncology & carcinogenesis, Thoracic diseases, COVID-19 (Malaltia) - Europa, Laboratoris anatòmics, localizaciones geográficas::Europa (continente) [DENOMINACIONES GEOGRÁFICAS], safety, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), lung neoplasms, pljučni rak, Geographic Locations::Europe [GEOGRAPHICALS], Specimen Handling, 03 medical and health sciences, Thoracic Diseases, udc:616.9, Humans, Pandemics, 030304 developmental biology, SARS-CoV-2, business.industry, pljučne novotvorbe, profesiones sanitarias::medicina::anatomía patológica::patología clínica [DISCIPLINAS Y OCUPACIONES], patologija, Human medicine, business, Biological Specimen Banks/organization & administration, Biological Specimen Banks/statistics & numerical data, COVID-19/epidemiology, COVID-19/prevention & control, COVID-19/virology, Clinical Laboratory Services/statistics & numerical data, Clinical Laboratory Services/trends, Containment of Biohazards/statistics & numerical data, Europe/epidemiology, Forecasting, Pathology, Clinical/methods, Pathology, Clinical/statistics & numerical data, Pathology, Clinical/trends, Pathology, Molecular/methods, Pathology, Molecular/statistics & numerical data, Pathology, Molecular/trends, SARS-CoV-2/isolation & purification, SARS-CoV-2/physiology, Specimen Handling/methods, Specimen Handling/statistics & numerical data, Thoracic Diseases/diagnosis, Thoracic Diseases/therapy
Abstract

Background This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases. Materials and methods A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019. Results Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples. Conclusions The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe., Highlights • Biosafety measures used in the first wave of the COVID-19 crisis were heterogeneous in 53 European pathology laboratories. • A dramatic decrease of the workload in pathology laboratories was noted. • No case of healthcare workers contaminated with SARS-CoV-2 associated with samples handling was identified.

Published
2021
Full Text
View/download PDF

10. Implementing TMB measurement in clinical practice: considerations on assay requirements.

Author

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, and Penault-Llorca F

Abstract

Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers that identify patients who are most likely to respond to immunotherapy. Comprehensive characterisation of tumours using genomic, transcriptomic, and proteomic approaches continues to lead the way in advancing precision medicine. Genetic correlates of response to therapy have been known for some time, but recent clinical evidence has strengthened the significance of high tumour mutational burden (TMB) as a biomarker of response and hence a rational target for immunotherapy. Concordantly, immune checkpoint inhibitors have changed clinical practice for lung cancer and melanoma, which are tumour types with some of the highest mutational burdens. TMB is an implementable approach for molecular biology and/or pathology laboratories that provides a quantitative measure of the total number of mutations in tumour tissue of patients and can be assessed by whole genome, whole exome, or large targeted gene panel sequencing of biopsied material. Currently, TMB assessment is not standardised across research and clinical studies. As a biomarker that affects treatment decisions, it is essential to unify TMB assessment approaches to allow for reliable, comparable results across studies. When implementing TMB measurement assays, it is important to consider factors that may impact the method workflow, the results of the assay, and the interpretation of the data. Such factors include biopsy sample type, sample quality and quantity, genome coverage, sequencing platform, bioinformatic pipeline, and the definitions of the final threshold that determines high TMB. This review outlines the factors for adoption of TMB measurement into clinical practice, providing an understanding of TMB assay considerations throughout the sample journey, and suggests principles to effectively implement TMB assays in a clinical setting to aid and optimise treatment decisions., Competing Interests: Competing interests: ER reports personal fees and non-financial support from AstraZeneca and Bristol-Myers Squibb. JL reports grants from Agilent Technologies and Roche Tissue Diagnostics, and personal fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Roche Tissue Diagnostics. FL-R reports personal fees from AstraZeneca, Bristol-Myers Squibb, Life Technologies, Merck, Pfizer, and Roche. FP-L reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche, and grants from NanoString. NN reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Qiagen, Roche, and Thermo Fisher Scientific, and grants and non-financial support from Merck. SM-B reports grants and personal fees from AstraZeneca and Novartis, and personal fees from Bristol-Myers Squibb and Roche. RB declares no conflicts of interest.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results